Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.

ABSTRACT: Background:There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL patients aged 19-88 years, but data on elderly patients have not been reported in detail so far. Here, we provide a subgroup analysis of patients??60 years treated on the R-CHOP14v21 trial with extended follow-up. Patients and methods:Six hundred and four R-CHOP14v21 patients??60 years were included in this subgroup analysis, with a median follow-up of 77.7?months. To assess the impact of MYC rearrangements (MYC-R) and double-hit-lymphoma (DHL) on outcome in elderly patients, we performed a joint analysis of cases with available molecular data from the R-CHOP14v21 (N?=?217) and RICOVER-60 (N?=?204) trials. Results:Elderly DLBCL patients received high dose intensities with median total doses of??98% for all agents. Toxicities were similar in both arms with the exception of more grade??3 neutropenia (P?

SUBMITTER: Kuhnl A 

PROVIDER: S-EPMC5815562 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature